Trials / Withdrawn
WithdrawnNCT03393481
Prevention of Thromboembolic Events in Total Knee Replacement Patients
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Active-controlled Phase 2 Study to Compare the Efficacy and Safety of s.c. MAA868 Versus s.c. Enoxaparin in Adult Patients Undergoing Unilateral Total Knee Arthroplasty
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to find out whether MAA868, is able to prevent blood clots following your medical condition (surgery for knee replacement)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAA868 | MAA868 dose 1 and dose 2, single administration, subcutaneous, |
| DRUG | Enoxaparin | Enoxaparin 40 mg, o.d X 10 days |
Timeline
- Start date
- 2018-10-03
- Primary completion
- 2020-01-08
- Completion
- 2020-04-17
- First posted
- 2018-01-08
- Last updated
- 2020-10-08
Source: ClinicalTrials.gov record NCT03393481. Inclusion in this directory is not an endorsement.